Eculizumab biosimilar (IBC GENERIUM)

依库珠单抗生物类似药 (IBC GENERIUM)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEculizumab biosimilar (IBC GENERIUM)

Drug Alias Name依库珠单抗生物仿制药 (IBC GENERIUM)Elizaria

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionComplement C5 inhibitors

TargetsComplement C5

Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesIbc Generium

China Registration ClassN/A

Active CompaniesIbc Generium

Inactive CompaniesN/A

Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome

Inactive IndicationsN/A

ATC CodeL04AJ01